News - Stealth BioTherapeutics Inc.

Stealth BioTherapeutics to Present at H.C. Wainwright Ophthalmology Virtual Healthcare Conference

BOSTON, Aug. 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the H.C. Wainwright Ophthalmology Virtual Conference on Tuesday, August 17, 2021 at ...

Aug 11, 2021

Stealth BioTherapeutics Reports Second Quarter 2021 Financial Results And Recent Business Highlights

BOSTON, Aug. 5, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the three months ended June 30, 2021 and announced recent business highlights. "We continue to make important ...

Aug 5, 2021

Stealth BioTherapeutics to Report Second Quarter Financial Results on Thursday, August 5

BOSTON, July 30, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report second quarter 2021 financial results on Thursday, August 5, before the market opens. Management will host a ...

Jul 30, 2021

Stealth BioTherapeutics Joins the Rare Disease Company Coalition

BOSTON, July 7, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has joined the Rare Disease Company Coalition, an alliance of life science companies committed to discovering, ...

Jul 7, 2021

Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Barth Syndrome

BOSTON, June 1, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) for elamipretide for the treatment of Barth ...

Jun 1, 2021

Stealth BioTherapeutics to Present at Jefferies Virtual Healthcare Conference

BOSTON, May 28, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the virtual Jefferies Healthcare Conference on Tuesday, June 1, 2021 at 3:00 p.m. ET. A ...

May 28, 2021

Stealth BioTherapeutics Reports First Quarter 2021 Financial Results And Recent Business Highlights

BOSTON, May 18, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the quarter ended March 31, 2021 and announced recent business highlights. "Our team is energized by the ...

May 18, 2021

Stealth BioTherapeutics Announces Additional Development Financing to Advance Elamipretide Clinical Trials

BOSTON, May 17, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has reached agreement with Morningside Ventures for Morningside to provide $30 million of additional payments to the ...

May 17, 2021

Stealth BioTherapeutics Announces Poster Presentation at American College of Cardiology (ACC) Annual Meeting

BOSTON, May 17, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company is presenting a poster at the 2021 American College of Cardiology (ACC) meeting being held virtually from May ...

May 17, 2021

Stealth BioTherapeutics to Present at Upcoming Investor Conferences in May

BOSTON, May 13, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the following upcoming virtual investor conferences in May: Oppenheimer's Rare & Orphan ...

May 13, 2021